scientific-pharmacovigilance

To identify post-market safety signals from FAERS adverse event data, you need to perform disproportionality analysis using PRR, ROR, IC, and EBGM calculations. This process evaluates statistical deviations to detect drug-associated risks. Applying MedDRA mappings ensures consistent terminology across your safety signal detection workflow.

Disproportionality analysis in pharmacovigilance works by calculating metrics such as PRR, ROR, IC, and EBGM to compare observed adverse event frequencies with expected baseline rates. This statistical method detects safety signals by revealing disproportionate drug-event associations within large datasets like FAERS.

To stratify pharmacovigilance safety patterns across time and demographics, apply temporal and demographic analysis techniques to your FAERS data. This approach reveals specific safety patterns across different patient populations and timeframes, supporting structured risk assessment workflows.

Yes, MedDRA mapping is required for consistent pharmacovigilance signal detection. Integrating FAERS-like adverse event data with MedDRA hierarchies standardizes medical terminology, which is essential for accurate disproportionality analysis and structured safety signal reporting.

The best way to generate structured safety signal reports from adverse event data is to execute consolidated disproportionality analyses using PRR, ROR, IC, and EBGM. This approach integrates temporal and demographic stratification to produce comprehensive risk assessment summaries.